Georgia's Online Cancer Information Center

Skin Cancer (Non-Melanoma) Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Skin Cancer (Non-Melanoma)
Cancer Type = Skin Cancer (Non-Melanoma)
There are currently 34 active Skin Cancer (Non-Melanoma) clinical trials in Georgia.
1.
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT01871727
Protocol IDs
E7777-G000-302
NCI-2013-00713
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Cancer Type
Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT01656603
Protocol IDs
6637-01
NCI-2016-01676
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
3.
NCORP Trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)
NCT ID
NCT02730312
Protocol IDs
XmAb14045-01
NCI-2016-00916
Treatment Sites (4)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
Cancer Type
Lung Cancer, Skin Cancer (Non-Melanoma)
NCT ID
NCT03319940
Protocol IDs
20160323
NCI-2017-02043
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Skin Cancer (Non-Melanoma), Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
8.
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies
Cancer Type
Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03218683
Protocol IDs
D6910C00001
NCI-2017-01390
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
A Phase 1b / 2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Cancer Type
Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT02554812
Protocol IDs
B9991004
NCI-2015-02263
2015-002552-27
JAVELIN MEDLEY
s16-02110
11.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03833167
Protocol IDs
3475-630
NCI-2019-01629
MK-3475-630
2018-001974-76
KEYNOTE-630
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03635983
Protocol IDs
CA045-001
NCI-2018-02224
17-214-08
2018-001423-40
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
14.
NCORP Trial
A Phase II Randomized Study of Adjuvant versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT03698019
Protocol IDs
S1801
S1801
NCI-2018-02107
Treatment Sites (1)
15.
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients with RM SCCHN Who Have Failed Platinum Based Therapy
Cancer Type
Head and Neck Cancer, Oral Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03468218
Protocol IDs
Winship4234-17
NCI-2017-02419
IRB00100269
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
16.
NCORP Trial
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Cancer Type
Skin Cancer (Non-Melanoma)
NCT ID
NCT03712605
Protocol IDs
EA6174
EA6174
NCI-2018-02217
Treatment Sites (1)
17.
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03038672
Protocol IDs
10089
10089
NCI-2017-00120
MC168D
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
18.
A Randomized Phase 2 Study of Rituxan Hycela in Patients with Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade with Nivolumab and Ipilimumab
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT03719131
Protocol IDs
Winship4457-18
NCI-2018-01804
IRB00105605
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
A Randomized Phase I Dose-Escalation Trial of Carfilzomib with and without Romidepsin in Cutaneous T-Cell Lymphoma
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT01738594
Protocol IDs
NU 12H06
NCI-2012-01952
IST-CAR-532
SP0021927
STU00071042
20.
NCORP Trial
A Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High Risk Anal Cancer
Cancer Type
Colon/Rectal Cancer, Skin Cancer (Non-Melanoma)
NCT ID
NCT03233711
Protocol IDs
EA2165
EA2165
NCI-2017-01347
21.
NCORP Trial
Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT03553836
Protocol IDs
3475-716
NCI-2018-01981
2018-000669-35
MK-3475-716
KEYNOTE 716
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
23.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Cancer Type
Colon/Rectal Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
24.
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (Poly-ICLC): An Adaptive, Multicenter, Phase II Clinical Study
Cancer Type
Skin Cancer (Non-Melanoma)
NCT ID
NCT02423863
Protocol IDs
ONC2014-001
NCI-2016-01295
1R44CA183075-01A1
25.
Integrated Pilot Biomarker Trial of VX15 / 2503 in Combination with Ipilimumab or Nivolumab in Patients with Head and Neck Cancer
Cancer Type
Skin Cancer (Non-Melanoma)
NCT ID
NCT03690986
Protocol IDs
Winship4402-18
NCI-2018-01263
IRB00103534
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
26.
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II / III Randomized Study of Chemoradiation versus Chemoradiation plus Atezolizumab
Cancer Type
Lung Cancer, Skin Cancer (Non-Melanoma)
NCT ID
NCT03811002
Protocol IDs
NRG-LU005
NRG-LU005
NCI-2019-00178
Treatment Sites (6)
27.
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Cancer Type
Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)
NCT ID
NCT03779854
Protocol IDs
RG1003345
NCI-2018-01752
9880
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
28.
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Selected Solid Tumors
Cancer Type
Lung Cancer, Pancreatic Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03485209
Protocol IDs
SGNTV-001
NCI-2018-00676
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
29.
Phase 1 / 2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Cancer Type
Breast Cancer, Cervical Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03674567
Protocol IDs
FLX475-02
NCI-2019-00102
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
30.
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Cancer Type
Cervical Cancer, Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT02503423
Protocol IDs
ASTX660-01
NCI-2017-01760
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
31.
Phase I / II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy
Cancer Type
Kidney Cancer, Lung Cancer, Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03656718
Protocol IDs
CA209-8KX
NCI-2018-02324
2018-001585-42
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
32.
Pilot Integrated Biomarker Study of VX15 / 2503 in Combination with Ipilimumab or Nivolumab in Patients with Resectable Metastatic Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT03769155
Protocol IDs
Winship4400-18
NCI-2018-01229
IRB00104273
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Cancer Type
Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer
NCT ID
NCT02595424
Protocol IDs
EA2142
EA2142
NCI-2015-00547
NCI-2015-00505
EA2142
Treatment Sites (4)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
34.
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma)
NCT ID
NCT03570892
Protocol IDs
CCTL019H2301
NCI-2018-02925
2016-002966-29
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.